LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

About this update from Aurinia Pharmaceuticals Inc

— New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress — ROCKVILLE, Md. & EDMONTON, Alberta --(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS® in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress ( EULAR 2026 Presentation ). This new analysis on the safety population of 356 patients (178 on LUPKYNIS and 178 on placebo) indicates that LUPKYNIS was associated with a statistically significant 53% reduction in the risk of renal-related event or death (hazard ratio=0.47; p=0.0007). Hazard ratios (HRs) favored treatment with LUPKYNIS for the following individual components of the composite endpoint: death (HR=0.19 [an 81% reduction in risk]; p=0.0929), treatment failure (HR=0.45 [a 55% reduction in risk]; p=0.0062) and worsening proteinuria (HR=0.22 [a 78% reduction in risk]; p

View stock analysis, news, and events for Aurinia Pharmaceuticals Inc